AstraZeneca buys drugmaker Caelum in deal worth up to $500 million By Reuters
© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
(Reuters) – AstraZeneca (NASDAQ:) said on Wednesday its newly acquired Alexion (NASDAQ:) division will purchase the remaining equity in drugmaker Caelum Biosciences in a deal that could be worth up to $500 million, expanding its access into rare-disease treatments.
The Anglo-Swedish drugmaker said it would take forward Caelum’s late-stage trial of a potential medicine to treat AL amyloidosis, a rare disease that affects the heart, kidneys and other organs.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
